ZeroFox (NASDAQ:ZFOX – Get Rating) had its price target cut by equities research analysts at Jefferies Financial Group from $4.50 to $3.00 in a note issued to investors on Monday, The Fly reports. The firm currently has a “hold” rating on the stock. Jefferies Financial Group’s price objective suggests a potential upside of 7.14% from the stock’s current price.
Separately, Stifel Nicolaus assumed coverage on ZeroFox in a report on Thursday, November 10th. They issued a “buy” rating and a $6.00 price objective for the company.
ZeroFox Stock Performance
ZFOX opened at $2.80 on Monday. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.34. ZeroFox has a one year low of $2.50 and a one year high of $15.73. The business’s 50-day simple moving average is $3.73 and its 200-day simple moving average is $4.69.
Institutional Investors Weigh In On ZeroFox
ZeroFox Company Profile
ZeroFox Holdings, Inc operates as an enterprise cybersecurity software-as-a-service company that addresses the full lifecycle of external cyber threats and risks. The company offers ZeroFox Protect that enables organizations to configure protective capabilities to identify and protect their external assets; ZeroFox Predict, a threat intelligence solution that enable customers to directly search across data lake of global threat indicators, tactics, adversary intelligence, exploits, vulnerabilities, and security tools; ZeroFox Detect that provides customers with real-time asset and vulnerability awareness for their external-facing internet digital footprint; ZeroFox Response that enables organizations to provide the 24×7 level of support necessary to respond to external attacks, incidents, data loss or exfiltration, or potential breaches; and ZeroFox Disrupt to report, block, and take down an attack's core components across the internet.
- Get a free copy of the StockNews.com research report on ZeroFox (ZFOX)
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets “Powelled”: S&P 500 Confirms Resistance
- Rivian Plummets, But Is This 2023’s Greatest Buying Opportunity?
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Receive News & Ratings for ZeroFox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZeroFox and related companies with MarketBeat.com's FREE daily email newsletter.